The presenting differential diagnosis of these patients would include cellulitis, but the presentation of the patients was not consistent with an infectious cause with, specifically, the lack of fever, induration, local discomfort, or increased warmth. Neither patient had a sense of malaise. Of significance in both patients was the painless intense pruritic nature of the erythema, which is also not consistent with cellulitis.
2-Octylcyanoacrylate is a monomer in liquid form. On contact with tissue anions (e.g., tissue, blood, fluid), there is rapid polymerization and binding to epidermal keratin in an exothermic reaction.2,3 It is touted that the speed of polymerization and high reactivity of the cyanoacrylate compound should prevent the molecule from being a strong immunosensitizer.1,3
The long-term treatment of contact dermatitis ideally is avoidance of the contact allergen. Short-term treatment includes removal of the offending material and possibly brief use of a topical steroid.1 Application of 2-octylcyanoacrylate should be avoided on open wounds or incompletely closed surgical incisions to avoid immunosensitization and subsequent development of allergy to cyanoacrylates.
Although contact dermatitis secondary to Dermabond is seemingly rare, plastic surgeons should be prepared to recognize the presence of 2-octylcyanoacrylate allergy and treat accordingly. The exanthem is hallmarked by intense painless pruritus. Treatment consists of removal of the Dermabond and consideration of short-term use of topical steroids.
Dr. Howard has not received any financial support from and has no financial interest in Ethicon, Inc. Dr. Downey has been a paid consultant for Ethicon, Inc., in the past.
Brian K. Howard, M.D.
Susan E. Downey, M.D.
Los Angeles, Calif.
1. Hivnor CM, Hudkins ML. Allergic contact dermatitis after postsurgical repair with 2-octylcyanoacrylate. Arch Dermatol
2. Ethicon, Inc. Dermabond package insert. Somerville, NJ: Ethicon, Inc.
3. Tomb RR, Lepoittevin JP, Durepaire F, Grosshans E. Ectopic contact dermatitis from ethyl cyanoacrylate instant adhesives. Contact Dermatitis
Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less time-sensitive than Letters and other types of articles. Please note the following criteria:
* Text-maximum of 500 words (not including references)
* References—maximum of five
* Authors—no more than five
* Figures/Tables—no more than two figures and/or one table
Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS' enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.
We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.